2. Metabolic Enzyme/Protease GPCR/G Protein Epigenetics Cell Cycle/DNA Damage Apoptosis NF-κB Stem Cell/Wnt TGF-beta/Smad
  3. Endogenous Metabolite G protein-coupled Bile Acid Receptor 1 PARP Apoptosis NF-κB PKA
  4. Taurodeoxycholate sodium

Taurodeoxycholate (sodium salt)  (Synonyms: タウロデオキシコール酸ナトリウム)

製品番号: HY-128853 純度: 99.80%
COA 取扱説明書 Technical Support

Taurodeoxycholate sodium salt is a bile salt-related anionic detergent. Taurodeoxycholate sodium salt is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholate sodium salt is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate (TDCA) exhibits anti-inflammatory and neuroprotective effects.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 1180-95-6

容量 価格（税別） 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 55 在庫あり
Solution
10 mM * 1 mL in DMSO USD 55 在庫あり
Solid
500 mg $50 在庫あり
1 g   お問い合わせ  
5 g   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 6 publication(s) in Google Scholar

Other Forms of Taurodeoxycholate sodium:

Taurodeoxycholate (sodium salt) 関連抗体

Top Publications Citing Use of Products

    Taurodeoxycholate sodium purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Feb 3:e2411719.  [Abstract]

    The mRNA levels of ALDOB in Huh7 or HCCLM3 cells treated with various bile acids (100 μM, 24 h). All data are presented as mean ± SD. Data were analyzed by one-way ANOVA with Bonferroni multiple-comparison correction. CA, cholic acid; TCA, taurocholic acid; GCA, glycocholic acid; TCDCA, taurochenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; LCA, lithocholic acid; TLCA, taurolithocholic acid; GLCA, glycolithocholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; GDCA, glycodeoxycholic acid; UDCA, ursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid.

    Endogenous Metabolite アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    Human Endogenous Metabolite Microbial Metabolite

    PARP アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    PARP PARP1 PARP2 PARP3 PARP4 TNKS1/PARP5A TNKS2/PARP5B PARP7 PARP10 PARP14 PARP15 PARP12 PARP16

    NF-κB アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

    PKA アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    PKA PKAR PKACα

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Taurodeoxycholate sodium salt is a bile salt-related anionic detergent. Taurodeoxycholate sodium salt is formed in the liver by conjugation of deoxycholate with Taurine (HY-B0351). Taurodeoxycholate sodium salt is used for isolation of membrane proteins including inner mitochondrial membrane proteins. Taurodeoxycholate (TDCA) exhibits anti-inflammatory and neuroprotective effects[1][2][3][9][10].

    体外実験

    Taurodeoxycholate sodium salt (Taurodeoxycholic acid form) shows agonist activity at human TGR5 expressed in CHO cells by luciferase assay, with an EC50 of 0.79 μM[4].
    Taurodeoxycholate sodium salt (Taurodeoxycholic acid form, 16 h) shows agonist activity at wild type and Y89A mutant human TGR5 expressed in HEK293 cells assessed as rise in intracellular cAMP level, with EC50s of 0.68 and 8.9 μM, respectively[5].
    Taurodeoxycholate sodium salt (Taurodeoxycholic acid form, 50 μM, 100 μM; 4 h) increases oligonucleosomal DNA cleavage and apoptotic nuclei in primary human hepatocytes[6].
    Taurodeoxycholate sodium salt (Taurodeoxycholic acid form, 400 μM, 18-24 h) increases DNA fragmentation and PARP cleavage in human liver-derived cell line Huh7 cells, thus induces apoptosis[8].
    Taurodeoxycholate (0.05-1.00 mM; 1-6 days) sodium salt stimulates intestinal epithelial cell proliferation[8].
    Taurodeoxycholate (0.05-1.00 mM; 24 h) sodium salt induces a significant increase in S-phase concentration and a significant decrease in G1-phase concentration of the cell cycle, increases c-myc protein and mRNA expression in IEC-6 cells[8].
    Taurodeoxycholate (25-400 ng/mL, with a four-fold dilution, 3 h) sodium salt inhibits the activation of NF-κB in lipopolysaccharide-activated bone marrow-derived macrophages (BMDMs) by activating the cAMP-PKA axis[9].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Taurodeoxycholate (sodium salt) 関連抗体

    Cell Proliferation Assay[8]

    Cell Line: IEC-6 and caco-2 cells
    Concentration: 0, 0.05, 0.50, and 1.00 mM
    Incubation Time: 1, 2, 4 and 6 days
    Result: Significantly stimulated intestinal epithelial cell proliferation in a dose-dependent manner.

    Cell Cycle Analysis[8]

    Cell Line: IEC-6 and caco-2 cells
    Concentration: 0, 0.05, 0.50, and 1.00 mM
    Incubation Time: 24 h
    Result: Significantly increased cells in S phase and decreased cells in G1-phase.

    Western Blot Analysis[8]

    Cell Line: IEC-6 and caco-2 cells
    Concentration: 0.5 mM
    Incubation Time: 1 and 6 days
    Result: Significantly increased c-myc protein expression.
    体内実験

    Taurodeoxycholate (1.25-5 mg/kg, p.o., 6 days) sodium salt ameliorates dextran sodium sulfate (DSS)-induced colitis in mice[9].
    Taurodeoxycholate sodium salt (Taurodeoxycholic acid form, 50 mg/kg; i.p.; once daliy for 34 d) prevents neuropathology and associated behavioral deficits in the 3-nitropropionic acid rat model of Huntington's disease (HD) [10].
    Taurodeoxycholate sodium salt (Taurodeoxycholic acid form, 500 mg/kg; s.c.; once every 3 d for 7 weeks) leads to a significant reduction in striatal neuropathology of the R6/2 transgenic HD mouse[11].
    Taurodeoxycholate (0.5 mg/kg; i.v., once) sodium salt confers protection to C57BL/6N mice with sepsis, but does not protect TGR5 KO mice under sepsis[12].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: A mouse colitis model (fed with 3% (w/v) DSS in drinking water for the first seven days and then switched to normal drinking water for an additional two days)[9]
    Dosage: 1.25, 2.5, and 5 mg/kg
    Administration: Oral gavage (p.o.), from day 3 to day 8, once a day
    Result: Prevented loss of body weight, shortening of the colon, production of pro-inflammatory cytokines, infiltration of pro-inflammatory cells, and mucosal ulceration in the colon.
    Animal Model: Huntington's disease model in mouse[10]
    Dosage: 50 mg/kg
    Administration: Intraperitoneal injection; once daliy for 34 d, injected 3-NP at 6 hr after Taurodeoxycholic acid treatment
    Result: Reduced striatal atrophy, decreased striatal apoptosis, as well as fewer and smaller size ubiquitinated neuronal intranuclear huntingtin inclusions.
    Significantly improved locomotor and sensorimotor deficits.
    Animal Model: C57BL/6N mice, Lipopolysaccharides (HY-D1056) injection model of sepsis[12]
    Dosage: 0.5 mg/kg
    Administration: Intravenous injection, 30 min or 24 h after LPS injection
    Result: Improved the survival rate of mice with sepsis.
    Decreased liver and kidney damage in septic mice.
    Ameliorated systemic inflammation and normalized blood pressure in septic mice.
    分子量

    521.69

    分子式

    C26H44NNaO6S
    CAS 番号
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    C[C@H](CCC(NCCS(=O)(O[Na])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C
    Structure Classification
    Initial Source
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
    溶剤 & 溶解度
    体外: 

    DMSO : 100 mg/mL (191.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.9168 mL 9.5842 mL 19.1685 mL
    5 mM 0.3834 mL 1.9168 mL 3.8337 mL
    10 mM 0.1917 mL 0.9584 mL 1.9168 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.08 mg/mL (3.99 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.08 mg/mL (3.99 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 99.80%

    COA (249 KB) RP-HPLC (251 KB)

    取扱説明書 (2659 KB)
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.9168 mL 9.5842 mL 19.1685 mL 47.9212 mL
    5 mM 0.3834 mL 1.9168 mL 3.8337 mL 9.5842 mL
    10 mM 0.1917 mL 0.9584 mL 1.9168 mL 4.7921 mL
    15 mM 0.1278 mL 0.6389 mL 1.2779 mL 3.1947 mL
    20 mM 0.0958 mL 0.4792 mL 0.9584 mL 2.3961 mL
    25 mM 0.0767 mL 0.3834 mL 0.7667 mL 1.9168 mL
    30 mM 0.0639 mL 0.3195 mL 0.6389 mL 1.5974 mL
    40 mM 0.0479 mL 0.2396 mL 0.4792 mL 1.1980 mL
    50 mM 0.0383 mL 0.1917 mL 0.3834 mL 0.9584 mL
    60 mM 0.0319 mL 0.1597 mL 0.3195 mL 0.7987 mL
    80 mM 0.0240 mL 0.1198 mL 0.2396 mL 0.5990 mL
    100 mM 0.0192 mL 0.0958 mL 0.1917 mL 0.4792 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Taurodeoxycholate sodium Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Taurodeoxycholate1180-95-6Endogenous MetaboliteG protein-coupled Bile Acid Receptor 1PARPApoptosisNF-κBPKAG-protein coupled receptor 19GPCR19TGR5GPBAR1poly ADP ribose polymerase Nuclear factor-κBNuclear factor-kappaBProtein kinase ABMDMsCHOHuh7IEC-6Huntington's diseaseColitisAnti-inflammatory.Inhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Taurodeoxycholate sodium
    製品番号:
    HY-128853
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.